Differential Regulation of Transforming Growth Factor β and Interleukin 2 Genes in Human T Cells: Demonstration by Usage of Novel Competitor DNA Constructs in the Quantitative Polymerase Chain Reaction

By B. Li, P. K. Sehajpal, A. Khanna, H. Vlassara,* A. Cerami,* K. H. Stenzel, and M. Suthanthiran

From The Rogosin Institute, Departments of Biochemistry and Medicine, Cornell University Medical College; and the *Laboratory of Medical Biochemistry, The Rockefeller University, New York, New York 10021

Summary

The regulation of mRNA encoding transforming growth factor β (TGF-β) and interleukin 2 (IL-2) in normal human T cells was explored using novel competitor DNA constructs in the quantitative polymerase chain reaction and accessory cell–independent T cell activation models. Our experimental design revealed the following: (a) TGF-β mRNA and IL-2 mRNA are regulated differentially in normal human T cells, quiescent or signaled with the synergistic combinations of: sn-1,2-dioctanoylglycerol and ionomycin or anti-CD3 monoclonal antibody (mAb) and anti-CD2 mAb; (b) the steady-state level of TGF-β mRNA in the stimulated T cells, in contrast to that of IL-2 mRNA, is increased by the immunosuppressant cyclosporine (CsA); and (c) the paradoxical effect of CsA on TGF-β mRNA levels is also appreciable at the level of production of functionally active TGF-β protein. Our findings, in addition to demonstrating the utility of the competitor DNA constructs for the precise quantification of immunoregulatory cytokines, suggest a novel and unifying mechanistic basis for the immunosuppression and some of the complications (e.g., renal fibrosis) associated with CsA usage.

Materials and Methods

Isolation and Activation of T Cells. T cells were isolated from normal human PBMC with a sequential multi-step procedure that yields >98% CD2 antigen-positive cells and <1% cells that are positive for the DR, CD14, CD25, or CD56 antigens (7). Accessory cell–independent T cell activation was accomplished with either sn-1,2-dioctanoylglycerol (DAG; 10.0 μg/ml) and ionomycin (1.0 μM) or crosslinked anti-CD2 (OKT11; 0.5 μg/ml) and anti-CD3 (OKT3; 0.5 μg/ml) mAbs (7).

Design and Synthesis of Competitor DNA Constructs. Fig. 1 illustrates the design, synthesis, and authentication of the 290-bp TGF-β competitor DNA construct created for the quantification of TGF-β mRNA by PCR. As shown, the oligonucleotide primer pair was designed to amplify a region in the TGF-β gene that contains a MseI restriction site. The MseI digestion of the 246-bp TGF-β PCR product yielded 210- and 36-bp subfragments that were annealed with a 44-bp DNA insert synthesized in vitro to have cohesive ends for the MseI restriction site. The phosphorylated 44-bp DNA fragment was ligated with the 210- and 36-bp DNA fragments using E. coli DNA ligase. After ligation, the mixture was run on a 2% low melting point agarose gel, and the 290-bp fragment was eluted and purified using the gene clean kit.

The 178-bp IL-2 competitor DNA construct was created in a similar fashion. Here, the phosphorylated 44-bp DNA insert was ligated with the 88- and 46-bp subfragments derived by MseI digestion of the 246-bp TGF-β PCR product.

Quantification by Competitive PCR. The cDNA, for quanti-
fication by competitive PCR (8), was synthesized in a reverse transcription reaction mixture containing 1 μg of total RNA (isolated from normal human T cells by the guanidinium isothiocyanate/cesium chloride method), 100 ng of random hexanucleotide primers, and 200 U of moloney murine leukemia virus reverse transcriptase. A constant amount of the cDNA (2 μl) was then amplified with known concentrations of the competitor DNA construct, for 32 cycles using 200 μM TGF-β or IL-2 gene-specific primer pairs in a reaction mixture (50 μl) containing 1× Taq buffer, 1 U Taq DNA polymerase, and 40 μM of each dNTP. The PCR products were resolved by 2% agarose gel electrophoresis, visualized by ethidium bromide staining, and photographed. The negative of the photographs was analyzed by laser densitometry, and the absolute absorbance values of the PCR products were determined. The ratios of the absorbance of the relevant PCR product pairs (290-bp TGF-β competitor and 246-bp TGF-β; 178-bp IL-2 competitor and 149-bp IL-2 PCR product) were plotted against the concentration of the competitor DNA used. The concentration of mRNA was thus determined and expressed as attomoles (amol) of TGF-β or IL-2 mRNA/mg of total RNA.

Results and Discussion

Differential Regulation of TGF-β mRNA and IL-2 mRNA. The steady-state levels of TGF-β mRNA and IL-2 mRNA in normal human T cells, quantified by competitive PCR, are displayed in Table 1. Several features that distinguish TGF-β mRNA regulation in T cells from that of IL-2 mRNA are apparent. First, in quiescent normal human T cells, TGF-β mRNA is readily quantifiable at every time point tested, and IL-2 mRNA is not detectable, at any of the time points evaluated, even by the application of the sensitive PCR methodology (Table 1). Second, quantitative and qualitative differences exist between TGF-β mRNA and IL-2 mRNA regulation in T cells signaled with the synergistic combination of DAG and ionomycin. As shown in Table 1, the concentration of IL-2 mRNA in the stimulated T cells is several-fold greater than that of TGF-β mRNA in the same T cell population, and the highest concentration of IL-2 mRNA is found 4 h after stimulation, and that of TGF-β mRNA 1 h after signaling of T cells with DAG and ionomycin.

The most striking difference between TGF-β mRNA regulation and that of IL-2 mRNA was evident when T cells, pretreated with CsA, were signaled with DAG and ionomycin. Whereas CsA completely prevented activation-dependent IL-2 mRNA accumulation in the T cells, the steady-state levels of TGF-β mRNA were increased by CsA (Table 1). The CsA-mediated increase in the abundance of TGF-β mRNA was best seen at the 1 h time point (Table 1).

Demonstration of Differential Regulation of TGF-β mRNA and IL-2 mRNA by Crosslinking the CD3 and CD2 Antigen on the T Cell Surface. Differential regulation of TGF-β mRNA and IL-2 mRNA, uncovered in this instance, by transmembrane signaling of T cells by crosslinkage of the CD3/TCR complex with the CD2 antigen is illustrated in Fig. 2. Laser densitometric scanning of the agarose gel electrophoresis analyses data displayed in Fig. 2 and its computation resulted in the following values (per mg of RNA from T cells): unstimulated T cells, 1,038 amol of TGF-β mRNA and undetectable level of IL-2 mRNA (Fig. 2, A1 and B1); T cells stimulated with crosslinked anti-CD3 and anti-CD2 mAbs, 1,992 amol of TGF-β mRNA and 17,170 amol of IL-2 mRNA (Fig. 2, A2 and B2); and T cells stimulated in the presence of CsA, 9,903 amol of TGF-β mRNA and undetectable level of IL-2 mRNA (Fig. 2, A3 and B3). Thus, CsA increased the steady-state level of TGF-β mRNA from 1,992 to 9,903 amol in T cells stimulated via cell surface proteins implicated in physiological antigenic signaling.

CsA Enhances TGF-β Protein Production. CsA's ability to augment TGF-β gene expression was evident at the level of production of functionally active TGF-β protein. As illustrated in Fig. 3, the highest levels of TGF-β protein were found in the supernatants of T cells pretreated with CsA and then signaled with either DAG and ionomycin or with cross-
Table 1. Differential Regulation of TGF-β mRNA and IL-2 mRNA in T Cells

| Exp. | Additions to T cells* | 1 h | 4 h | 16 h | 40 h |
|------|----------------------|-----|-----|------|------|
|      | TGF-β | IL-2 | TGF-β | IL-2 | TGF-β | IL-2 | TGF-β | IL-2 |
| 1    | None | 657 | <20 | 406 | <20 | 228 | <20 | 200 | <20 |
|      | DAG + Iono | 2,408 | 2,736 | 441 | 24,419 | 172 | 2189 | 147 | 21 |
|      | CsA + DAG + Iono | 5,488 | <20 | 744 | <20 | 238 | <20 | 213 | <20 |
| 2    | None | 360 | <20 | 441 | <20 | 431 | <20 | 294 | <20 |
|      | DAG + Iono | 625 | 3,449 | 253 | 37,832 | 544 | 366 | 272 | 57 |
|      | CsA + DAG + Iono | 1,567 | <20 | 685 | <20 | 272 | <20 | 413 | <20 |
| 3    | None | 431 | <20 | 463 | <20 | 156 | <20 | 147 | <20 |
|      | DAG + Iono | 653 | 129 | 259 | 192,050 | 147 | 232 | 169 | 78 |
|      | CsA + DAG + Iono | 1,085 | <20 | 222 | <20 | 181 | <20 | 131 | <20 |

* Highly purified T cells (10⁶ cells/ml) were incubated with the agents shown for 1, 4, 16, or 40 h. Total RNA was then isolated, reverse transcribed into cDNA, and amplified by PCR. The amount of TGF-β mRNA was quantified by using the 290-bp TGF-β competitor DNA construct and the IL-2 mRNA with the 178-bp IL-2 competitor DNA construct in the competitive PCR. DAG, 10.0 μg/ml; ionomycin, 1.0 μM; CsA, 100 ng/ml.

linked anti-CD2 and anti-CD3 mAbs. The bioactivity (growth inhibition of mink lung epithelial cells) was best observed after acidification of the T cell supernatants and was inhibited, in each instance, by an avian anti-TGF-β antibody (Fig. 3 B).

Conclusions and Implications. TGF-β, a potent inhibitor of T cell growth and differentiation, is considered also as a fibrogenic cytokine (1, 2). Our observation that CsA enhances TGF-β gene expression, thus, suggests a novel and unifying mechanism for the immunosuppression as well as for the renal fibrosis encountered with CsA usage. Our investigation also suggests a new hypothesis for the CsA-mediated inhibition of new DNA synthesis by T cells (since TGF-β inhibits c-myc gene expression and c-myc expression contributes to T-cell growth [9]) and for the CsA-associated vasoconstriction and hypertension (since TGF-β enhances the expression of the potent vasoconstrictor, endothelin [10]).

CsA has selective inhibitory effects on the appearance of DNA regulatory proteins (11). Thus, prevention by CsA of

Figure 2. Differential regulation of TGF-β and IL-2 mRNA in T cells. Serial dilutions of the 290-bp TGF-β construct or the 178-bp IL-2 construct were coamplified with the cDNA from unstimulated T cells (A1 and B1), T cells stimulated with anti-CD2 mAb and anti-CD3 mAb (A2 and B2), or T cells pretreated with CsA (100 ng/ml) and stimulated with anti-CD2 mAb and anti-CD3 mAb (A3 and B3). The mRNA levels, found after 1 h of incubation of T cells, are shown and are provided in the text. M, 123-bp repeat ladder.
the emergence of nuclear regulatory factors that bind to the negative regulatory sequence of the TGF-β gene or the lack of inhibition by CsA of DNA regulatory proteins that promote TGF-β gene expression might be responsible for our results. These hypotheses as well as whether CsA differentially regulates TGF-β and IL-2 gene expression in vivo are to be explored in our future studies.

We thank Dr. Vijay K. Sharma for expert technical help, Dr. Kirk Manogue for careful reading of the manuscript and useful suggestions, Dr. Albert L. Rubin for encouragement, and Ms. Lorraine Goldberg Garcia for the meticulous secretarial help in the preparation of this manuscript.

This work was supported in part by U.S. Public Health Service grant AI-26932 (M. Suthanthiran) and by The American Cancer Society grant CN-30 (A. Cerami).

Address correspondence to M. Suthanthiran, Immunogenetics and Transplantation Center, The Rogosin Institute, 430 East 71st Street, New York, NY 10021.

Received for publication 3 July 1991 and in revised form 30 August 1991.

References
1. Roberts, A.B., and M.B. Sporn. 1988. Transforming growth factor β. Adv. Cancer Res. 51:107.
2. Massague, J. 1990. The transforming growth factor-β family. Annu. Rev. Cell Biol. 6:597.
3. Kehrl, J.H., L.M. Wakefield, A.B. Roberts, S. Jakowlew, M. Alvarez-Mon, R. Derynck, M.B. Sporn, and A.S. Fauci. 1986. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 163:1037.
4. Smith, K.A. 1988. Interleukin-2: inception, impact, and implications. Science (Wash. DC). 240:1169.
5. Wallick, C.S., I.S. Figari, R.E. Morris, A.D. Levinson, and M.A. Palladino, Jr. 1990. Immuno-regulatory role of transforming growth factor β (TGF-β) in development of killer cells: comparison of active and latent TGF-β. J. Exp. Med. 172:1777.
6. Granelli-Piperno, A., L. Andrus, and R.M. Steinman. 1986. Lymphokine and nonlymphokine mRNA levels in stimulated human T cells: kinetics, mitogen requirements and effects of cyclosporine A. J. Exp. Med. 163:922.
7. Sehajpal, P., A. Subramaniam, V.K. Murthy, V.K. Sharma, and M. Suthanthiran. 1989. Demonstration of a direct inhibitory effect of cyclosporine on normal human T-cells with two novel models of T-cell activation as probes. Cell. Immunol. 120:195.
8. Gilliland, G., S. Perrin, K. Blanchard, and H.F. Bunn. 1990. Analysis of cytokine mRNA and DNA. Detection and quantification by competitive polymerase chain reaction. Proc. Natl. Acad. Sci. USA. 87:2725.
9. Heikkila, R., G. Schwab, E. Wickstrom, S.L. Loke, D.H. Puzniak, R. Watt, and L.M. Neckers. 1987. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progression from G0 to G1. Nature (Lond.). 328:445.
10. Kurihara, H., M. Yoshizumi, T. Sugiyama, F. Takaku, M. Yanagisawa, T. Masaki, M. Hamaoki, H. Kato, and Y. Yazaki. 1989. Transforming growth factor-β stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem. Biophys. Res. Commun. 159:1435.
11. Emmel, E.A., C.I. Verweij, D.B. Durand, K.M. Higgins, E. Lacy, and G.R. Crabtree. 1989. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science (Wash. DC). 246:1617.